Grey Matters Health Inc. is a clinical stage pharmaceutical development company operating in Canada and Australia. The company focuses on advancing therapeutic drugs targeting non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke programs. Its pipeline features repirinast, developed for the treatment of chronic kidney disease, and N,N-Dimethyltryptamine for addressing strokes and traumatic brain injuries. Grey Matters Health Inc. concentrates on the life sciences sector, specifically pharmaceuticals and biotech, contributing to innovative treatments for serious metabolic, renal, and neurological conditions. Listed on the Canadian Securities Exchange, it represents a player in the emerging clinical-stage drug development market, emphasizing research and pipeline progression in high-need therapeutic areas.